Comparative Pharmacology
Head-to-head clinical analysis: CAVERJECT versus CAVERJECT IMPULSE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CAVERJECT versus CAVERJECT IMPULSE.
CAVERJECT vs CAVERJECT IMPULSE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Causes relaxation of corpus cavernosum smooth muscle and vasodilation via increased intracellular cyclic guanosine monophosphate (cGMP) due to inhibition of phosphodiesterase type 5 (PDE5) by its active metabolite, alprostadil.
Alprostadil is a synthetic prostaglandin E1 that causes vasodilation and relaxation of trabecular smooth muscle in the corpus cavernosum, leading to increased blood flow and penile erection.
Initial dose 2.5 micrograms intracavernous injection, titrate to effect; maximum 60 micrograms per injection. Frequency no more than 3 times per week with at least 24 hours between doses.
2.5 to 60 mcg intracavernosal injection as needed for erection, maximum 3 times per week with at least 24 hours between doses. Initial dose: 2.5 mcg, titrate based on response.
None Documented
None Documented
Terminal elimination half-life is 1-2 hours; clinically, plasma levels decline rapidly after injection, with minimal systemic accumulation.
Terminal elimination half-life is approximately 1-2.5 minutes following intravenous administration, due to rapid pulmonary metabolism; after intracavernosal injection, local half-life is extended to about 30-60 minutes due to depot effect.
Renal: 70-80% as metabolites, 20-30% unchanged; biliary/fecal: <5%
Primarily metabolized in the lung by enzymatic hydrolysis; urinary excretion accounts for approximately 70-90% of the administered dose as metabolites, with less than 3% excreted unchanged in urine; fecal excretion is minimal (<1%).
Category C
Category C
Prostaglandin
Prostaglandin